Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - sycrest
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpf2aa2b90d380444519f71c2efd9d6e1e
identifier: http://ema.europa.eu/identifier
/EU/1/10/640/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Sycrest 5 mg sublingual tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-f2aa2b90d380444519f71c2efd9d6e1e
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/10/640/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - sycrest
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Sycrest contains the active substance asenapine. This medicine belongs to a group of medicines called antipsychotics. Sycrest is used to treat moderate to severe manic episodes associated with bipolar I disorder in adults. Antipsychotic medicines affect the chemicals that allow communication between nerve cells (neurotransmitters). Illnesses that affect the brain, such as bipolar I disorder, may be due to certain chemicals in the brain, such as dopamine and serotonin, being out of balance and these imbalances may cause some of the symptoms you may be experiencing. Exactly how this medicine works is unknown, however, it is believed to adjust the balance of these chemicals.
Manic episodes associated with bipolar I disorder is a condition with symptoms such as feeling high , having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Do not take Sycrest If you are allergic to asenapine or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Sycrest.
Sycrest has not been studied in elderly patients with dementia. However, elderly patients with dementia, who are treated with other similar types of medicine, may have an increased risk of stroke or death. Sycrest is not approved for the treatment of elderly patients with dementia and is not recommended for use in this particular group of patients.
Sycrest may cause low blood pressure. In the early stages of treatment, some people may faint, especially when getting up from a lying or sitting position. This will usually pass on its own but if it does not, tell your doctor. Your dose may need to be adjusted.
Asenapine may cause sleepiness, sudden drops in blood pressure when you stand up, dizziness and changes in your ability to move and balance, which may lead to falls and, consequently, fractures or other injuries. Patients at risk for fall should be evaluated prior to prescribing asenapine.
Tell your doctor immediately if you experience
involuntary rhythmic movements of the tongue, mouth and face. Withdrawal of Sycrest may be needed.
fever, severe muscle stiffness, sweating or a lowered level of consciousness (a disorder called neuroleptic malignant syndrome ). Immediate medical treatment may be needed.
Check with your doctor or pharmacist before taking Sycrest:
if you have ever been diagnosed with a condition whose symptoms include high body temperature and muscle stiffness (also known as neuroleptic malignant syndrome).
if you have ever experienced abnormal movements of the tongue or face (tardive dyskinesia). You should be aware that both of these conditions may be caused by this type of medicine.
if you have a heart disease or a treatment for heart disease that makes you prone to low blood pressure
if you are diabetic or prone to diabetes
if you have Parkinson s disease or dementia
if you have epilepsy (seizures)
if you experience any difficulty in swallowing (dysphagia)
if you have severe liver problems. If you do, you should not take Sycrest
if you have difficulty controlling core body temperature
if you have thoughts of suicide
if you have abnormally high levels of prolactin in the blood (hyperprolactinaemia)
Be sure to tell your doctor if you meet any of these conditions as he/she may want to adjust your dose or monitor you for a while. Also contact your doctor immediately if any of these conditions develops or worsens while using Sycrest.
Children and adolescents Sycrest is not recommended for use in patients below the age of 18 years.
Other medicines and Sycrest Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Some medicines may reduce or increase the effect of Sycrest.
If you are taking other medicines, Sycrest should be taken last.
You should tell your doctor if you are taking antidepressant medicines (specifically fluvoxamine, paroxetine or fluoxetine), as it may be necessary to change your Sycrest or antidepressant medicine dose.
You should tell your doctor if you are taking medicines for Parkinson s disease (such as levodopa), as this medicine may make them less effective.
Since Sycrest works primarily in the brain, interference from other medicines (or alcohol) that work in the brain could occur due to an additive effect on brain function.
Since Sycrest can lower blood pressure, care should be taken when Sycrest is taken with other medicines that lower blood pressure.
Sycrest with food, drink and alcohol Do not eat or drink for 10 minutes after taking this medicine. You should avoid drinking alcohol when taking this medicine. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Do not take Sycrest while you are pregnant, unless your doctor tells you so. If you are taking this medicine and you become pregnant or you plan to get pregnant, ask your doctor as soon as possible whether you may continue taking Sycrest.
The following symptoms may occur in newborn babies, of mothers that have used Sycrest in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.
Do not breast-feed when taking Sycrest.
Driving and using machines Sycrest may cause sleepiness or sedation. Therefore, make sure your concentration and alertness are not affected before you drive or operate machinery.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is a sublingual tablet of 5 mg or 10 mg two times a day. One dose should be taken in the morning and one dose should be taken in the evening.
Instructions for use Sycrest is for sublingual use. Sycrest is not advised if you are unable to take the tablet as described below. If you are unable to take this medicine as is described below, the treatment may not be effective for you.
Figure 1 Figure 2 Figure 3
If you take more Sycrest than you should If you take too much Sycrest, contact a doctor straight away. Take the medicine pack with you. In case of overdose you may feel sleepy or tired, or have abnormal body movements, problems with standing and walking, feel dizzy due to low blood pressure and feel agitated and confused.
If you forget to take Sycrest Do not take a double dose to make up for a forgotten dose. If you miss one dose, take your next dose as usual. If you miss two or more doses, contact your doctor or pharmacist.
If you stop taking Sycrest If you stop taking Sycrest, you will lose the effects of this medicine. You should not stop taking this medicine, unless your doctor tells you as your symptoms may return.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects have been reported with this medicine. Seek medical attention immediately if you have any of the following symptoms:
Tell your doctor right away if you have:
Other side effects reported with this medicine include:
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and on the carton. The expiry date refers to the last day of that month.
Store this medicine in the original package in order to protect from light and moisture.
This medicinal product does not require any special temperature storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Sycrest contains
The active substance is asenapine.
Each Sycrest 5 mg sublingual tablet contains 5 mg asenapine.
Each Sycrest 10 mg sublingual tablet contains 10 mg asenapine.
The exact amount is shown on your Sycrest tablet pack.
The other ingredients are gelatin and mannitol (E421).
What Sycrest looks like and contents of the pack The 5 mg sublingual tablets are round white to off-white tablets marked with 5 on one side. The 10 mg sublingual tablets are round white to off-white tablets marked with 10 on one side.
The sublingual tablets are provided in peelable blisters containing 10 tablets each. Packs may contain 20, 60 or 100 tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder N.V. Organon Kloosterstraat 6 NL-5349 AB Oss The Netherlands
Manufacturer Organon Heist bv Industriepark 2220 Heist-op-den-Berg, Belgium
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Organon Belgium T l/Tel: 0080066550123 (+32 2 2418100)
dpoc.benelux@organon.com
Lietuva Organon Pharma B.V. Lithuania atstovyb
Tel.: +370 52041dpoc.lithuania@organon.com
( . .) . . -
.: +359 2 806 3dpoc.bulgaria@organon.com
Luxembourg/Luxemburg Organon Belgium T l/Tel: 0080066550123 (+32 2 2418100)
dpoc.benelux@organon.com
esk republika Organon Czech Republic s.r.o. Tel: +420 233 010 dpoc.czech@organon.com
Magyarorsz g Organon Hungary Kft. Tel.: +36 1 766 1dpoc.hungary@organon.com
Danmark Organon Denmark ApS
Tlf: +45 4484 6info.denmark@organon.com
Malta Organon Pharma B.V., Cyprus branch Tel: +356 2277 8dpoc.cyprus@organon.com
Deutschland Organon Healthcare GmbH Tel.: 0800 3384 726 (+49 (0) 89 2040022 10) dpoc.germany@organon.com
Nederland N.V. Organon Tel: 00800 66550123 (+32 2 2418100) dpoc.benelux@organon.com
Eesti Organon Pharma B.V. Estonian RO Tel: +372 66 61 dpoc.estonia@organon.com
Norge Organon Norway AS Tlf: +47 24 14 56 info.norway@organon.com
BIANE . . : +30 210 80091 Mailbox@vianex.gr
sterreich Organon Healthcare GmbH Tel: 0800 3384 726 (+49 (0) 89 2040022 10) dpoc.austria@organon.com
Espa a Organon Salud, S.L. Tel: +34 91 591 12 organon_info@organon.com Polska Organon Polska Sp. z o.o. Tel.: +48 22 105 50 organonpolska@organon.com
France Organon France T l: +33 (0) 1 57 77 32 Portugal Organon Portugal, Sociedade Unipessoal Lda. Tel: +351 218705geral_pt@organon.com
Hrvatska Organon Pharma d.o.o. Tel: +385 1 638 4dpoc.croatia@organon.com
Rom nia Organon Biosciences S.R.L. Tel: +40 21 527 29 dpoc.romania@organon.com
Ireland Organon Pharma (Ireland) Limited Tel: +353 15828medinfo.ROI@organon.com
Slovenija Organon Pharma B.V., Oss, podru nica Ljubljana Tel: +386 1 300 10 dpoc.slovenia@organon.com
sland Vistor hf. S mi: +354 535 7Slovensk republika Organon Slovakia s. r. o. Tel: +421 2 44 88 98 dpoc.slovakia@organon.com
Italia Organon Italia S.r.l. Tel: +39 06 90259dpoc.italy@organon.com
Suomi/Finland Organon Finland Oy Puh/Tel: +358 (0) 29 170 3dpoc.finland@organon.com
Organon Pharma B.V., Cyprus branch : +357 22866dpoc.cyprus@organon.com
Sverige Organon Sweden AB Tel: +46 8 502 597 dpoc.sweden@organon.com
Latvija rvalsts komersanta Organon Pharma B.V.
p rst vniec ba Tel: +371 66968dpoc.latvia@organon.com
United Kingdom (Northern Ireland) Organon Pharma (UK) Limited
Tel: +44 (0) 208 159 3medicalinformationuk@organon.com
This leaflet was last revised in {month/YYYY}.
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-f2aa2b90d380444519f71c2efd9d6e1e
Resource Composition:
Generated Narrative: Composition composition-en-f2aa2b90d380444519f71c2efd9d6e1e
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/10/640/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - sycrest
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpf2aa2b90d380444519f71c2efd9d6e1e
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpf2aa2b90d380444519f71c2efd9d6e1e
identifier:
http://ema.europa.eu/identifier
/EU/1/10/640/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Sycrest 5 mg sublingual tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en